Skip to main content

ERRATUM article

Front. Immunol., 12 December 2022
Sec. Cancer Immunity and Immunotherapy
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1114331

Erratum: Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer

This article is an erratum on:

  1. Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer

By Wu Y, Yao Z, Zhang J, Han C, Kang K and Zhao A (2022) Front. Immunol. 13:1058819. doi: 10.3389/fimmu.2022.1058819

Due to a production error, there was a mistake on the first line of the Methods section where the number of patients with metastatic NSCLC was incorrectly captured as “298,48patients” when it should have been “298,485 patients”.

A correction has been made to the Abstract section, subsection Methods:

“In this cohort study, 298,485 patients with metastatic NSCLC diagnosed between 2000 and 2018 were identified from the Surveillance, Epidemiology, and End Results Program. Unsupervised clustering with Bayesian inference method was performed for all patients’ death causes, which separated them into two death patterns: the pre-immunotherapy era group and the immunotherapy era group. Relative risk (RR) of each death cause between two groups was estimated using Poisson regression. Reduced death risk as survival time was calculated with locally weighted scatterplot smooth (Lowess) regression.”

The publisher apologizes for this mistake.

The original version of this article has been updated.

Keywords: death cause analysis, immunotherapy, non-small cell lung cancer, metastatic disease, real world data

Citation: Frontiers Production Office (2022) Erratum: Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer. Front. Immunol. 13:1114331. doi: 10.3389/fimmu.2022.1114331

Received: 02 December 2022; Accepted: 02 December 2022;
Published: 12 December 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.